Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for weight loss in people living with HIV and obesity
2019-002314-39Phase 2Active
- Sponsor
- University College Dublin
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide in human immunodeficiency virus infection (HIV) and obesity (2 arms), sponsored by University College Dublin. Primary endpoint: Change from baseline in total body weight at week 28. Started Oct 2020; status: active.
02
Drugs
03
Conditions
human immunodeficiency virus infection (HIV)obesity
Beyond the preview
Go deeper on 2019-002314-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002314-39.